🔗 Share this article

An underground market for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on communication apps, according to recent findings.

Experimental Drug Gaining Traction Online

Retatrutide, which remains in clinical trials, is being advertised by social media influencers for its supposed weight-reducing effects. Viewers are encouraged to contact these profiles directly for supplier links, while also receiving discount codes.

Thriving Trade on Messaging Platforms

Additionally, a robust trade exists on Telegram, where communities with thousands of participants share “before and after” photos, injection guides and assertions of next-day UK delivery. Sellers promote the drug there before directing customers to WhatsApp for purchases.

Understanding Retatrutide

Retatrutide is an investigational injectable developed by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Preliminary studies suggest it could assist patients lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being hailed digitally as the next Ozempic.

Healthcare Professionals Express Worries

Nevertheless, physicians and pharmacists have cautions that the sale of what is still an unapproved medication in the UK is a cause for concern and could lead to individuals injecting substances of uncertain source.

Several experts said the demand for the experimental drug could be linked to the rising price of licensed weight loss treatments such as Mounjaro.

Regulatory Position and Implementation

Marketing the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unlicensed medication that must not be marketed or supplied for personal consumption under the Human Medicines Regulations 2012.

Several content creators attempt to sidestep the regulations by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a controlled drug, but advertising and distribution can still breach pharmaceutical, marketing, and consumer laws, potentially leading to fines, legal action or imprisonment.

Service Response and Material Removal

Based on the social media company, the service has taken down problematic content and banned associated keywords and search suggestions. The organization stated it was dedicated to maintaining the platform secure and investing in enhancing compliance measures.

Digital Trading Activities

Research also discovered communities with up to nine thousand members selling the experimental drug using Telegram's integrated search feature, which operates like a online catalog. Typing “retatrutide” instantly brings up channels with numerous of members, filled with images of weight loss, positive testimonials and detailed guides for preparing or administering at home.

Within moments of entering one community, a vendor shared contact information, where most purchases take place. The vendor provided an instruction manual and guaranteed delivery within two days. When questioned whether the product was genuine, one vendor responded: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. None inquired about weight, medical conditions or previous experience.

Item Details and Costs

Within these groups, messages display dark colored packages with postal service labels, stating to include new batches. One communication read: “It took eight of us to load them this morning.”

Customers can select between dry substance containers, mixed at home with sterile water, or ready-to-use pens usually sold at £160 for 20 milligrams. When questioned how long a pen should be used, vendors give conflicting answers ranging from a several days to “depends on your body”.

Service Oversight and Security Actions

A spokesperson for Telegram stated it regularly moderated dangerous material on its service including content that promoted the “misuse of controlled medications”. The company noted that it removed “millions of pieces of harmful content each day”.

Medical Expert Warnings

“Individuals are administering materials they cannot confirm. Although the research behind retatrutide is valid, these online products may not include what they advertise,” stated a pharmacy expert, the head of pharmacy at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor connected the surge in interest to current cost increases for approved slimming medications such as Mounjaro. “With prices rising, individuals are using social media. But fake treatments are extremely risky. You can’t be certain what’s inside or whether the conditions they were made in was sterile,” she said.

Her staff has previously seen patients harmed by personal administration from unverified suppliers. “We understand the frustration, but purchasing from messaging apps or communication platforms is gambling with your well-being,” stated the doctor. “These materials could be contaminated or incorrectly dosed.”

Manufacturer Position

A representative from Eli Lilly stated retatrutide was in phase 3 research studies and had not been evaluated or authorized by any government authority anywhere in the world. “Therefore at this time no one can market [it] for human use,” they explained, adding that any product “falsely representing itself as a company investigational product not yet authorized … may expose patients to potentially serious medical dangers”.